Clinical Trial

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-08
Trial Details
NCT Number NCT07382739
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Pfizer
Conditions Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM), Extramedullary Disease in Multiple Myeloma, Paramedullary Disease, PMD
Enrollment 34 participants
Start Date 2026-03-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-14